Leike Zhang
Overview
Explore the profile of Leike Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
6636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xu H, Jian X, Wen Y, Xu M, Jin R, Wu X, et al.
EBioMedicine
. 2024 Jan;
99:104944.
PMID: 38176215
Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne pathogen that causes severe hemorrhagic fever in humans, but no FDA-approved specific antivirals or vaccines are available to...
12.
Xu M, Xu H, Wan W, Jian X, Jin R, Wang L, et al.
Viruses
. 2023 Dec;
15(12).
PMID: 38140584
Mammalian arenaviruses are rodent-borne zoonotic viruses, some of which can cause fatal hemorrhagic diseases in humans. The first discovered arenavirus, lymphocytic choriomeningitis virus (LCMV), has a worldwide distribution and can...
13.
Salikhov S, Abdurakhmonov I, Oshchepkova Y, Ziyavitdinov J, Berdiev N, Aisa H, et al.
Front Med (Lausanne)
. 2023 Dec;
10:1310129.
PMID: 38093975
Clinical Trial Registration: ClinicalTrials.gov, ID NCT05862883.
14.
Wang B, Zhang L, Deng F, Hu Z, Wang M, Liu J
Virol Sin
. 2023 Nov;
39(1):113-122.
PMID: 38008382
Severe fever with thrombocytopenia syndrome (SFTS) caused by the SFTS virus (SFTSV) is an emerging disease in East Asia with a fatality rate of up to 30%. However, the viral-host...
15.
Wang H, Yang Q, Liu X, Xu Z, Shao M, Li D, et al.
Nat Commun
. 2023 Nov;
14(1):7574.
PMID: 37990007
Since 2019, SARS-CoV-2 has evolved rapidly and gained resistance to multiple therapeutics targeting the virus. Development of host-directed antivirals offers broad-spectrum intervention against different variants of concern. Host proteases, TMPRSS2...
16.
Wang X, Ma X, Liu X, Zhang L, Tian Y, Ye C
Water Sci Technol
. 2023 Oct;
88(8):1982-2001.
PMID: 37906454
For the low efficiency and large loss of cascade pumping stations, aiming to maximize system efficiency, an optimized scheduling model of cascade pumping stations is established with consideration of multiple...
17.
Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, et al.
Nat Commun
. 2023 Oct;
14(1):6463.
PMID: 37833261
The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here,...
18.
Jiang Z, Feng B, Zhang Y, Nie T, Liu H, Li J, et al.
Signal Transduct Target Ther
. 2023 Oct;
8(1):407.
PMID: 37833245
No abstract available.
19.
Zhang Y, Sun Y, Xie Y, Shang W, Wang Z, Jiang H, et al.
Signal Transduct Target Ther
. 2023 Sep;
8(1):360.
PMID: 37735468
During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and...
20.
Ren P, Li H, Nie T, Jian X, Yu C, Li J, et al.
J Med Chem
. 2023 Aug;
66(17):12266-12283.
PMID: 37594952
3CL is an attractive target for the treatment of COVID-19. Using the scaffold hopping strategy, we identified a potent inhibitor of 3CL () that contains a thiocyanate moiety as a...